Seneca Partners, the specialist SME investment business based in the North West, has invested £1.2m into biotech company, SolasCure to support the development of their wound cleaning product, Aurase® through the Seneca EIS Portfolio Service and Seneca Growth Capital VCT.  Seneca’s investment comes as SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds.